有希望的结果，但需要谨慎的GLP-1RA大规模流行病学。

Trends in Endocrinology & Metabolism Pub Date : 2025-04-24 DOI:10.1016/j.tem.2025.03.015

Salil V Deo,Naveed A Sattar

{"title":"有希望的结果，但需要谨慎的GLP-1RA大规模流行病学。","authors":"Salil V Deo,Naveed A Sattar","doi":"10.1016/j.tem.2025.03.015","DOIUrl":null,"url":null,"abstract":"Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis. However, many apparent novel findings need testing or validation in randomized trials.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Promising results but caution needed in GLP-1RA large scale epidemiology.\",\"authors\":\"Salil V Deo,Naveed A Sattar\",\"doi\":\"10.1016/j.tem.2025.03.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis. However, many apparent novel findings need testing or validation in randomized trials.\",\"PeriodicalId\":23301,\"journal\":{\"name\":\"Trends in Endocrinology & Metabolism\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Endocrinology & Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tem.2025.03.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tem.2025.03.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Xie等人调查了胰高血糖素样肽1受体激动剂（GLP1-RAs）与美国糖尿病退伍军人175例健康结果的发病率之间的关系，最近报道了心脏疾病和物质使用障碍的风险较低，但胰腺炎、胃肠道疾病和关节炎的风险较高。然而，许多明显的新发现需要在随机试验中进行测试或验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Promising results but caution needed in GLP-1RA large scale epidemiology.

Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis. However, many apparent novel findings need testing or validation in randomized trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in Endocrinology & Metabolism

自引率

0.00%

发文量